New Assets and Facility to Advance Sustainable Farming
Syngenta has taken a significant step in biologicals research by acquiring Novartis’ collection of natural products and genetic strains for agricultural use. This acquisition, part of Syngenta’s broader commitment to sustainable farming, will enhance its ability to develop next-generation biological solutions.
Under this agreement, Novartis retains pharmaceutical rights to the repository, while Syngenta gains access to advanced bioengineering, fermentation, and analytics capabilities. The company will also lease Novartis’ fermentation pilot plant and laboratories in Basel, Switzerland, strengthening its global research network.
Simultaneously, Syngenta has launched a biologicals production facility in Orangeburg, South Carolina, USA. This world-class facility will support increasing demand for biological products in the North and Latin American markets, reinforcing Syngenta’s role as a leader in sustainable agriculture.
Syngenta has also partnered with multiple agricultural technology companies to accelerate innovation -
Camilla Corsi, Syngenta’s Global Head of Crop Protection Research and Development, stated, “We invest significantly to offer the industry’s most advanced pipeline of innovative agricultural solutions.”
Jonathan Brown, Global Head of Syngenta’s Seedcare and Biologicals business, added, “With the broadest and most comprehensive portfolio across all segments of biological products, we have established ourselves as a leader in the industry.”
Biologicals, including biocontrols, biostimulants, and nutrient use efficiency products, are key to regenerative agriculture. They help farmers improve soil health, reduce chemical dependence, and enhance sustainability.
Syngenta’s expansion in this sector builds upon its 2020 acquisition of Valagro.
Photo Credit: syngenta-plants-scientists